This site is intended for healthcare professionals

Find disease awareness content and relevant supporting materials

News 12 Drugs 41 Trials 4 Journals 17
Filter results
Sort by:
Relevance
to
Drug information
06/05/20

Actelsar HCT 40 mg/12.5 mg tablets & Actelsar HCT 80 mg/12.5 mg tablets

Treatment of essential hypertension. Actelsar HCT fixed dose combination (40 mg telmisartan/12.5 mg hydrochlorothiazide and 80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.

  • 29 min read
Drug information
06/05/20

Actelsar HCT 80 mg/25 mg tablets

Treatment of essential hypertension. Actelsar HCT fixed dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

  • 29 min read
Drug news
25/11/11

Sevikar HCT (Daiichi Sankyo) now available in the UK

Sevikar HCT (olmesartan medoxomil, amlodipine besylate plus hydrochlorothiazide) from Daiichi Sankyo Europe, the first three-in-one pill to treat Hypertension, has...

  • 1 min read
Drug news
28/09/12

Generic Diovan HCT launched in USA

The US patent on Diovan (valsartan) and the combination product Diovan HCT (valsartan plus the diuretic hydrochlorothiazide) from Novartis has...

  • 1 min read
Industry news
05/01/18

ANI Pharma acquires Atacand, Atacand HCT, Arimidex and Casodex US rights from AstraZeneca.

ANI Pharmaceuticals, Inc. announced that it has acquired the NDAs and U.S. rights to market Atacand, Atacand HCT, Arimidex, and...

  • 1 min read
Drug news
05/01/18

ANI Pharmaceuticals acquires US rights to Atacand, Atacand HCT, Arimidex and Casodex from AstraZeneca.

ANI Pharmaceuticals, Inc. announced that it has acquired the NDAs and U.S. rights to market Atacand, Atacand HCT, Arimidex, and...

  • 1 min read
Drug news
04/03/17

Final results of aAdVise study of brincidofovir for the treatment of adenovirus (AdV) infection in allogeneic hematopoietic cell transplant (HCT) recipients.-Chimerix.

Chimerix announced the presentation of final data from the AdVise trial of brincidofovir for the treatment of adenovirus (AdV) infection...

  • 1 min read
Journal
25/03/20

Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research

Trends in utilization and outcomes after autologous or allogeneic hematopoietic cell transplantation (HCT) for Burkitt Lymphoma (BL) were analyzed in...

  • 1 min read
  • Source: Biology of Blood and Marrow Transplantation
Journal
25/03/20

Intermittent Zolendronic Acid Prevents Bone Loss in Adults after Allogeneic Hematopoietic Cell Transplantation

Bone mineral density (BMD) loss is common in survivors of allogeneic hematopoietic cell transplantation (alloHCT). We performed a multi center...

  • 1 min read
  • Source: Biology of Blood and Marrow Transplantation
Journal
25/03/20

The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients

The hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of early death and survival in elderly patients with acute myeloid...

  • 1 min read
  • Source: Leukemia Research
See more